Eterna Therapeutics Investigates ERNA-101 in Cancer Models
Eterna Therapeutics, a preclinical-stage company, announced a research collaboration with MD Anderson Cancer Center to evaluate its lead induced mesenchymal stem cell therapy, ERNA-101, for treating ovarian and breast cancers. ERNA-101, a proprietary allogenic cell therapy, aims to stimulate antitumor immunity. The research will assess ERNA-101’s effects both in vitro and in vivo, with potential future studies exploring […]